Search Results

approved by the FDA for ATC. 31 Single-agent paclitaxel may benefit some newly diagnosed patients; increased survival has been reported in patients with stage IVB disease. 77 – 79 If weekly paclitaxel is used, the ATA guidelines recommend using paclitaxel

with clinical stage T1N1 or T2–3N0–1 disease were eligible, and were randomized to either 41.4 Gy of radiotherapy over 5 weeks with concurrent weekly carboplatin (area under the curve, 2) and paclitaxel (50 mg/m 2 ) followed by surgery, or to surgery

regional or distant metastatic CSCC. Those most commonly used are cisplatin, carboplatin, and 5-FU, either as monotherapy or combination regimens. 66 – 76 For the 2022 update, the panel voted to include carboplatin ± paclitaxel under options useful in

chemotherapy. 47 Based on a patient’s response to systemic chemotherapy (ie, stable disease, partial or complete response), surgical consolidation may be considered thereafter. Pagliaro et al 42 recently reported that neoadjuvant chemotherapy with paclitaxel

(response rate, 32% vs 9%; median OS, 11.1 vs 6.8 months, respectively) in a group of patients with metastatic PCA. 5 More recently, the combination of gemcitabine and nab-paclitaxel has likewise proven to be superior to gemcitabine alone for patients with

months with combination therapies (gemcitabine/nab-paclitaxel or FOLFIRINOX). 3 , 4 Despite numerous phase II/III studies of PDAC in the past decade, treatment options remain limited. 5 Advances in other solid tumors have been possible due to biomarker

regimens included (1) cisplatin + either pemetrexed (nonsquamous only) or gemcitabine (squamous only); or (2) carboplatin + paclitaxel (any histology). If their patients could not tolerate cisplatin, clinicians could substitute carboplatin-based regimens

-label phase II trial demonstrated superior efficacy of T-DXd compared with physician’s choice of paclitaxel or irinotecan, with improvements across all metrics, including ORR (51% vs 14%), as well as median PFS and OS (5.6 vs 3.5 months and 12.5 vs 8.4 months

urothelial bladder cancer. 115 – 118 Based on these results, several groups are exploring 2- and 3-drug combinations using these agents, with and without cisplatin. A randomized phase III trial was conducted to compare GC and GC plus paclitaxel in 626

single-agent chemotherapy, such as gemcitabine or capecitabine, and 35.4% (n=57) would offer multiagent chemotherapy, such as FOLFIRINOX or gemcitabine/nab-paclitaxel. Bivariate Analyses: A consistent relationship was seen between vignette